Michael Huber

Michael Huber has a diverse work experience in finance-related roles. Michael started as a Controller at Birkart Globistics from 2001 to 2007. Then, they worked at Mundipharma from 2007 to 2017, progressing from Controller CEE to Head of Finance CEE & Austria. After that, they served as Interim Head of Finance at Coface in 2017. From 2019 to 2020, they worked as Head of Finance & Organizational Project Manager at AOP Orphan Pharmaceuticals AG. Later in 2019, they became the Head of Finance & Business Services at Amomed Pharma GmbH. Currently, they hold the position of Head of Finance at Merz Therapeutics since 2021.

Michael Huber attended WU (Vienna University of Economics and Business) from 2014 to 2018, where they pursued a Master of Legal Studies.